SOFDRA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SOFDRA (SOFDRA).
SOFDRA (sodium oxybate) is a CNS depressant that acts primarily via GABA-B receptors and also via a specific receptor for gamma-hydroxybutyrate (GHB). It is hypothesized to normalize nocturnal sleep architecture and improve daytime sleepiness in narcolepsy.
| Metabolism | Sodium oxybate is primarily metabolized by the enzyme GHB dehydrogenase (a form of aldehyde dehydrogenase) and to a minor extent via CYP450 (not a major pathway). Metabolism is saturable and follows first-order kinetics at therapeutic doses. |
| Excretion | Primarily hepatic metabolism with renal excretion of inactive metabolites; <1% excreted unchanged in urine; biliary/fecal elimination accounts for approximately 20% of total clearance. |
| Half-life | Terminal elimination half-life is 6-9 hours in healthy adults; may be prolonged up to 12-15 hours in patients with hepatic impairment. |
| Protein binding | Approximately 95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 0.8-1.2 L/kg, indicating extensive extravascular distribution. |
| Bioavailability | Oral bioavailability is approximately 75% due to first-pass metabolism; intravenous bioavailability is 100%. |
| Onset of Action | Intravenous administration: within 5-10 minutes; oral administration: 30-60 minutes. |
| Duration of Action | Clinical effect persists for 6-8 hours following a single dose; duration may be extended in patients with hepatic dysfunction. |
1 drop (0.3 mg) in each eye once daily in the evening. Ophthalmic solution.
| Dosage form | GEL, METERED |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established. |
| Geriatric use | No dosage adjustment required; systemic exposure is similar to that in younger adults. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SOFDRA (SOFDRA).
| Breastfeeding | No data on presence in human milk, effects on breastfed infant, or milk production. Because of the potential for serious adverse reactions (e.g., anticholinergic effects, including constipation and urinary retention) in breastfeeding infants, breastfeeding is not recommended during treatment with sofdrA. M/P ratio unknown. |
| Teratogenic Risk | Sofdra (sofpironium bromide) is an anticholinergic agent. In animal reproduction studies, no structural abnormalities were observed at doses up to 3 times the maximum recommended human dose; however, anticholinergic drugs may cause fetal tachycardia and reduced fetal heart rate variability. Use in pregnancy should be avoided unless clearly needed. First trimester: limited data; no known major malformations. Second and third trimesters: potential for fetal anticholinergic effects, including decreased fetal movement and heart rate variability. |
■ FDA Black Box Warning
WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and RISK OF ABUSE. SOFDRA is a CNS depressant and can cause respiratory depression, hypotension, profound sedation, coma, and death. Concomitant use of alcohol or other CNS depressants increases these risks. SOFDRA is a Schedule III controlled substance with potential for abuse and dependence.
| Serious Effects |
["Concomitant use of alcohol or other CNS depressants (e.g., benzodiazepines, opioids)","Succinic semialdehyde dehydrogenase deficiency","Severe hepatic impairment (Child-Pugh C)","History of substance abuse (relative contraindication)"]
| Precautions | ["Central nervous system depression and respiratory depression","Risk of abuse and dependence (Schedule III controlled substance)","Sodium content (high sodium intake may be problematic in patients with hypertension, heart failure, or renal impairment)","Suicidal ideation and depression (monitor for psychiatric symptoms)","Parasomnias (sleepwalking, confusional arousals)","Requires strict adherence to dosing schedule (twice nightly, taken at bed and 2.5-4 hours later)"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, and anticholinergic symptoms (dry mouth, constipation, blurred vision). If used during pregnancy, consider fetal monitoring for heart rate variability and movement. No routine fetal monitoring required based on current data. |
| Fertility Effects | No human data on fertility effects. In animal studies, no impairment of mating or fertility at doses up to 3 times the MRHD. Theoretical anticholinergic effects on reproductive tract function have not been studied. |